Cyclophosphamide/methylprednisolone/prednisone

Cyclophosphamide/methylprednisolone/prednisone Reactions 1680, p103 - 2 Dec 2017 Cyclophosphamide/ methylprednisolone/prednisone Various toxicities: case report A 75-year-old woman developed herpes zoster, influenza A infection, bacteraemia secondary to the Rothia species following treatment with methylprednisolone, cyclophosphamide and prednisone. The woman, who was diagnosed with IgA nephropathy with superimposed pauci-immune anti-neutrophilic cytoplasmic antibody (ANCA)- associated crescentic glomerulonephritis, received three doses of IV methylprednisolone 1000 mg/day, followed by oral prednisone 60 mg/day, in the hospital. Following a renal biopsy after the initial treatment, IV cyclophosphamide 700mg was administered on day 12 of hospitalisation. Later, she was discharged. One month thereafter, she received her second dose of cyclophosphamide. Eight days later, she was admitted to the ICU for generalised malaise and fever with a right-sided vesicular rash in a dermatomal distribution on the trunk, suggesting herpes zoster. The woman was treated with acyclovir. Subsequently, she developed influenza A infection, bacteraemia secondary to the Rothia species and diarrhoea [not all durations of treatments to reactions onset stated]. Thus, she received treatment with metronidazole, vancomycin and oseltamivir. Consequently, she recovered from all the infections. Author comment: "Unfortunately, most immunosuppressive regimens carry life-threatening risks including infection-related complications, especially in the elderly population." Nissaisorakarn P, et al. ANCA and IgA glomerulonephritis all in one: Prognosis and complications. BMJ Case Reports 2017: 9 Oct 2017. Available from: URL: http://doi.org/10.1136/bcr-2017-222080 - USA 803285410 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Cyclophosphamide/methylprednisolone/prednisone

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/cyclophosphamide-methylprednisolone-prednisone-jsMtWaLWxt
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39034-8
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial